If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

Share Price is delayed by 15 minutes
Get Live Data
34.00    0.00 (0.00%)
Bid:
33.00
Ask:
35.00
Spread: 2.00 (6.061%)
Market Cap: £18.30m
COG Live PriceLast checked at - London Stock Exchange

Intraday Cambridge Cog Share Chart

Grant of Options

4 May 2021 11:52

RNS Number : 4778X
Cambridge Cognition Holdings PLC
04 May 2021
Β 

Cambridge Cognition Holdings Plc

Β 

("Cambridge Cognition" or the "Company")

Β 

Grant of Options

Β 

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, announces that on 30 April 2021, the Company granted options ("Options") over a total of 446,500 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") pursuant to the Company's EMI option scheme and its unapproved option scheme.

Of these Options:

1. 231,500 were granted to Persons Discharging Managerial Responsibilities ("PDMRs") on behalf of the Company;

Name

Role

Number of Options Granted

Total number of Options held following Grant

Total number of Ordinary Shares held

Percentage of Current Issued Share Capital Held

Matthew Stork

Chief Executive Officer

90,000

783,061

125,000

0.40%

Michael Holton

Chief Financial Officer

35,000

35,000

-

Ricky Dolphin

Chief Technology Officer

35,000

265,634

-

Fiona Cree

Chief Operating Officer

35,000

211,857

-

-

Richard Cooper

Chief Commercial Officer

36,500

208,286

-

-

Β 

2. 215,000 were granted to other employees of the Company.

Of the Options granted:

1. 230,000 of those Options granted to PDMRs and all the Options granted to other employees are exercisable at a price of 125 pence per Ordinary Share from three years following the date of award until the tenth anniversary of the date of award, subject to satisfying the following performance criteria:

a. 50% of the Options granted will vest if the average closing mid-market price of an Ordinary Share for any three month period exceeds 142 pence, with the price on the last day of that period being at least 120 pence, and the last day of this period being no later than 30 April 2024; and

b. 50% of the Options granted will vest if the average closing mid-market price of an Ordinary Share for any three month period exceeds 170 pence, with the price on the last day of that period being at least 145 pence, and the last day of this period being no later than 30 April 2024.

Β 

2. The remaining 1,500 options granted to PDMRs are exercisable at a price of 1 pence per Ordinary Share from two years following the date of award until the tenth anniversary of the date of award. All of these Options are granted over shares already in issue and held by Cambridge Cognition Trustees Limited on behalf of the Employee Benefit Trust.

Following the grant of Options, the total number of Options outstanding over unissued Ordinary Shares is 2,731,136 representing approximately 8.76% of the Company's issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Names

Matthew Stork - Chief Executive Officer

Michael Holton - Chief Financial Officer

Ricky Dolphin - Chief Technology Officer

Fiona Cree - Chief Operating Officer

Richard Cooper - Chief Commercial Officer

2.

Reason for the Notification

a)

Position/status

See 1(a) above for positions - all classified as PDMRs of the Company

b)

Initial notification/ Amendment

Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Cambridge Cognition Holdings Plc

b)

LEI

213800SZKDIN122EPA96

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

In each case, the grant of Options over Ordinary Shares on 30 April 2021

Β 

Identification code

GB00B8DV9647

b)

Nature of the transaction

Grant of Options over Ordinary Shares

Β 

c)

Price(s) and volume(s)

Price: n/a

Volumes:

Matthew Stork - 90,000 Options

Michael Holton - 35,000 Options

Ricky Dolphin - 35,000 Options

Fiona Cree - 35,000 Options

Richard Cooper - 36,500 Options

d)

Aggregated information:

Β· Aggregated volume

Β· Price

n/a

e)

Date of the transaction

30 April 2021

f)

Place of the transaction

Outside a trading venue

Β 

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014

Enquiries

Cambridge Cognition Holdings PLC

Matthew Stork, Chief Executive Officer

Michael Holton, Chief Financial Officer

Tel: 01223 810 700

press@camcog.com

finnCap Ltd (NOMAD and Joint Broker)

Tel: 020 7220 0500

Geoff Nash / Simon Hicks

(Corporate Finance)

Alice Lane/ Manasa Patil

(Corporate Broking)

Β 

Dowgate Capital Limited (Joint Broker)

David Poutney/ James Serjeant

Tel: 020 3903 7715

(Corporate Broking)

IFC Advisory Limited (Financial PR and IR)

Tel: 020 3934 6630

Tim Metcalfe/ Graham Herring/ Zach Cohen

Β 

Β 

Β 

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
DSHBZLFBFELEBBF
Date   Source Headline
16th Dec 20249:20 amRNSDirector/PDMR Share Purchases
10th Dec 20247:00 amRNSTrading Update
18th Nov 20244:02 pmRNSHolding(s) in Company
6th Nov 20247:00 amRNSMonument Therapeutics secures £1m investment
18th Oct 20247:00 amRNSDirectorate Change
10th Oct 202412:44 pmRNSBlock Listing Return
12th Sep 202412:38 pmRNSDirectorate change
22nd Aug 20247:00 amRNSInterim Results
20th Aug 20247:00 amRNSNotice of Results
12th Aug 202412:15 pmRNSHolding(s) in Company
26th Jul 20247:00 amRNSIssue of Equity and Total Voting Rights
23rd Jul 20247:00 amRNSTrading Update & Board Change
11th Jul 20247:00 amRNSCambridge Cognition secures Innovate UK grant
1st Jul 20244:20 pmRNSHolding(s) in Company
1st Jul 20247:00 amRNSGrant of Options
28th Jun 20241:48 pmRNSResult of AGM & Change of Name of NOMAD & Broker
21st Jun 202411:23 amRNSHolding(s) in Company
20th Jun 20242:15 pmRNSHolding(s) in Company
20th Jun 20242:15 pmRNSHolding(s) in Company
17th Jun 202412:33 pmRNSResults of GM, Open Offer, TVR and PDMR Dealing
6th Jun 20247:00 amRNSNotice of AGM
31st May 20247:00 amRNSCircular Publication and Notice of General Meeting
30th May 20247:00 amRNSResult of Placing and Subscription
29th May 20244:39 pmRNSProposed Placing, Subscription and Open Offer
1st May 20247:00 amRNSPreliminary Results, Trading Update & Board Change
30th Apr 20247:00 amRNSNotice of Results
23rd Apr 20247:00 amRNSCOG spin-out Monument Therapeutics accesses £1.5m
2nd Apr 20244:20 pmRNSTotal Voting Rights and Block Listing Return
21st Mar 20247:00 amRNSFormation of new Scientific Advisory Board
21st Feb 202410:16 amRNSHolding(s) in Company
21st Feb 20247:00 amRNSCambridge Cognition and ActiGraph Partnership
30th Jan 20244:20 pmRNSDirector/PDMR Share Purchases
30th Jan 20247:00 amRNSBoard appointments
30th Jan 20247:00 amRNSTrading Update
18th Dec 20237:00 amRNSGrant of Options
1st Dec 20237:00 amRNSTotal Voting Rights
22nd Nov 20237:00 amRNSChange of Auditor
1st Nov 20237:00 amRNSTotal Voting Rights
24th Oct 20237:00 amRNSAutomated quality assurance for clinical trials
11th Oct 20237:00 amRNSMajor contract win combining solutions
5th Oct 20235:33 pmRNSIssue of Warrants
3rd Oct 20232:43 pmRNSBlock listing Interim Review
28th Sep 20233:35 pmRNSHolding(s) in Company
26th Sep 20237:01 amRNSInterim Results
26th Sep 20237:00 amRNSSecured £3 million Term Loan
4th Sep 20237:00 amRNSNotice of Interim Results
3rd Jul 20237:00 amRNSTotal Voting Rights
28th Jun 20234:26 pmRNSResult of AGM
13th Jun 20237:00 amRNS£2m contract for a pivotal cancer therapy trial
9th Jun 20237:00 amRNSNotice of AGM – Revision to Explanatory Note

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.